XML 67 R58.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Contingencies and commitments (Details) $ in Millions |  |  |  |  |  |  |  | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 18, 2017 patent | Oct. 07, 2017 patent | Oct. 06, 2017 patent | Oct. 05, 2017 defendants | Sep. 22, 2017 USD ($) | Sep. 14, 2017 lawsuit | Aug. 24, 2017 lawsuit | Sep. 30, 2017 lawsuit
Sensipar (cinacalcet) Patent Litigation [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Gain contingency, number of lawsuits filed |  |  |  |  |  |  |  | 18
KYPROLIS (carfilzomib) Patent Litigation [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Gain contingency, number of lawsuits filed |  |  |  |  |  | 3 | 2 | 10
Sensipar (cinacalcet) Patent Litigation, Consolidated by Delaware District Court [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Gain contingency, number of lawsuits filed |  |  |  |  |  |  |  | 15
Epoetin Alfa Litigation [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Litigation settlement, length of trial |  |  |  |  | 5 days |  |  |
Litigation settlement, amount awarded from other party | $ |  |  |  |  | $ 70 |  |  |
Subsequent event [Member] | Sanofi/Regeneron [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Loss contingency, number of defendants | defendants |  |  |  | 2 |  |  |  |
Subsequent event [Member] | Mvasi Patent Litigation, Genentech, Inc. (Genentech) and the City of Hope [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Gain contingency, patents allegedly infringed upon, number | patent |  |  | 27 |  |  |  |  |
Loss contingency, patents allegedly infringed, number | patent | 25 | 24 |  |  |  |  |  |

X
- Definition Gain Contingency, Number of Lawsuits Filed + References No definition available. + Details
Name: | amgn_GainContingencyNumberofLawsuitsFiled
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation Settlement, Length of Trial + References No definition available. + Details
Name: | amgn_LitigationSettlementLengthofTrial
Namespace Prefix: | amgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded from other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of defendants named in a legal action. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_SensiparcinacalcetPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_KYPROLIScarfilzomibPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_SensiparcinacalcetPatentLitigationConsolidatedbyDelawareDistrictCourtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_EpoetinAlfaLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_SanofiRegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=amgn_MvasiPatentLitigationGenentechInc.GenentechandtheCityofHopeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |